Objectives: To compare the performance of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI breakpoints following their revision in 2010, for the detection of extended-spectrum blactamase (ESBL) production in Enterobacteriaceae.
Introduction
The prevalence of extended-spectrum b-lactamase (ESBL) production in strains of the Enterobacteriaceae family, such as Escherichia coli, Klebsiella spp. and Enterobacter spp., has been increasing continuously during the past decade in Europe and worldwide. 1 -4 The production on ESBLs can lead to lifethreatening infections with increased morbidity, mortality and healthcare-associated costs. 5 -8 The Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) recently changed their recommendations concerning the interpretation and reporting of in vitro drug susceptibility testing (DST) results. These changes apply to penicillins, cephalosporins and monobactams, and are based on limited clinical data, pharmacokinetics/pharmacodynamics (PK/PD) properties and MIC distributions.
If the production of an ESBL was confirmed, both institutions until 2009 recommended to edit all in vitro susceptible and intermediate DST results for penicillins, cephalosporins and monobactams to 'resistant' (CLSI), 9 or to change interpretative categories 'susceptible' and 'intermediate' to 'intermediate' and 'resistant', respectively (EUCAST). 10 In 2010 EUCAST published inhibitionzone diameter susceptibility breakpoints for cephalosporins in Enterobacteriaceae that were significantly higher than CLSI breakpoints up to 2009. 11 In parallel, CLSI increased zone diameter susceptibility breakpoints as well. 12 Currently, editing of in vitro susceptibility test results for b-lactams in ESBL-producing isolates is no longer recommended. 13, 14 However, for epidemiological and infection control purposes, screening for ESBL production in Enterobacteriaceae is still useful (CLSI) 13 or even mandatory (EUCAST). 14 In isolates producing an AmpC-type b-lactamase, phenotypic detection of ESBL production is often hampered by the interference of AmpC with ESBL screening and confirmatory tests leading to false reports to clinicians and, thus, to inadequate therapy. 15, 16 In addition, unnecessary time, effort and cost are generated in the laboratories to further study false-positive ESBL screening tests resulting from the low specificity of ESBL screening methods in AmpC-positive isolates. 16 As a tool to counter this problem, cloxacillin-containing Muller -Hinton agar, which inhibits AmpC activity, has been successfully evaluated. 17 Furthermore, cefepime may be the most suitable cephalosporin for ESBL detection in AmpC-positive isolates since it is less affected by AmpC than other third-generation cephalosporins, such as ceftazidime, cefotaxime, cefpodoxime and ceftriaxone. 15 The rapid advance of molecular methods for the detection of ESBL has raised the question of using these techniques as routine screening methods. 18 -20 However, implementation in routine clinical diagnostic laboratories is complex and needs personal resources with specialist qualifications. Moreover, the costs of molecular screening methods for multidrug-resistant isolates are still significantly higher than those for phenotypic methods. 21 In this study the performance of CLSI screening breakpoints for ESBL detection in clinical isolates were compared with EUCAST breakpoints for a set of phenotypically and genotypically well-characterized Enterobacteriaceae isolates. Many clinical laboratories in Europe are currently adopting the EUCAST system, although a direct comparison of the performance of CLSI and EUCAST standards has not yet been reported. EUCAST does not provide specific screening breakpoints for ESBL; therefore, EUCAST inhibition zone diameter clinical breakpoints for thirdgeneration cephalosporins were applied as determinants for ESBL production.
Methods

Clinical isolates
The 236 Enterobacteriaceae clinical isolates used in this study have previously been systematically characterized for the production of ESBL and/or AmpC-type b-lactamases, using phenotypic and molecular methods (for ESBL, S. Polsfuss, G. V. Bloemberg, J. Giger, V. Meyer, E. C. Bottger and M. Hombach, unpublished results). 22 All isolates had initially been screened for potential ESBL production on the basis of: (i) positive CLSI screening breakpoint values for ESBL for at least one thirdgeneration cephalosporin (cefpodoxime and/or ceftazidime and/or ceftriaxone and/or cefotaxime); and (ii) observation of a synergy zone between amoxicillin/clavulanic acid and cefpodoxime and/or ceftazidime and/or ceftriaxone and/or cefotaxime. For 118/236 isolates ESBL production was confirmed by molecular methods, while another 118/236 isolates were ESBL-negative (see Table 1 ).
Susceptibility testing
For susceptibility testing the disc diffusion method according to KirbyBauer was used. Antibiotic discs (Becton Dickinson, Franklin Lakes, NJ, USA) were selected, and results were interpreted according to the 2011 guidelines of EUCAST and CLSI. 13, 14 Screening breakpoint values are shown in Tables 2 -4. Susceptibility testing was performed on Mueller-Hinton agar (bioMérieux, Marcy L'Etoile, France) using McFarland 0.5 with overnight cultures and incubated at 358C for 16 -18 h. Polsfuss et al. Tables 2-4) .
Disc approximation method (DAM)
DAM with amoxicillin/clavulanic acid was conducted as described. 23 Synergy phenomena were recorded between amoxicillin/clavulanic acid discs (20/10 mg/disc) and/or cefepime (30 mg/disc), and/or EUCAST cefotaxime (5 mg/disc), and/or EUCAST ceftazidime (10 mg/disc), and/or CLSI cefotaxime (30 mg/disc) and/or CLSI ceftazidime (30 mg/disc) discs. Antibiotic discs were placed 30 mm apart (centre to centre). b-Lactam inhibitor-mediated enhancement of a third-generation cephalosporin inhibition zone was interpreted as synergy positive. Molecular methods were considered the gold standard for the calculation of performance parameters.
Results
Comparison of CLSI and EUCAST inhibition zone breakpoints for third-generation cephalosporins
For cefotaxime, overall sensitivity of EUCAST non-susceptible breakpoints for ESBL with corresponding EUCAST loaded discs equalled those of CLSI ESBL screening breakpoints/loads (sensitivity 99.2%, see also Table 2 ). If the EUCAST resistant breakpoint was applied, sensitivity decreased from 99.2% (1/118 ESBLproducing isolates not detected) to 94.9% (6/118 ). For ceftazidime, sensitivity of the EUCAST non-susceptible breakpoint for ESBL with corresponding EUCAST disc content was higher than that for the CLSI ESBL screening breakpoint/load (77.1% and 65.3% for EUCAST and CLSI, respectively). If the EUCAST resistant breakpoint was applied, sensitivity equalled that of the CLSI breakpoint/disc content. When the EUCAST non-susceptible breakpoint for ceftriaxone was used, sensitivity for ESBL detection compared with the CLSI ESBL screening breakpoint/disc content was lower (95.8% versus 99.2%, respectively). For cefpodoxime the non-susceptible EUCAST breakpoint showed higher sensitivity for ESBL detection compared with the CLSI ESBL screening breakpoint/load (100% versus 98.3%, respectively).
In AmpC-producing isolates (n¼ 91), of which 13 were ESBL positive (see Table 1 ), all diameter breakpoints showed low specificities for ESBL detection, except the EUCAST breakpoints for cefepime, which displayed a specificity of 82.1% and 96.2% for the non-susceptible and resistant breakpoints, respectively (Table 3) .
In non-AmpC-producing isolates (n ¼145) the EUCAST nonsusceptible breakpoint for cefpodoxime was the most sensitive single marker for ESBL production (sensitivity 100%, see Table 4 ). In comparison, the corresponding CLSI breakpoint showed a sensitivity of 98.1% (2 out of 105 ESBL-producing isolates not detected). Sensitivities of EUCAST and CLSI breakpoints for cefotaxime were equal (99.0%, 1 out of 105 ESBL positive isolates not detected). For third-generation cephalosporins, only the EUCAST non-susceptible breakpoint for ceftriaxone showed lower sensitivity in non-AmpC-producing isolates than the CLSI ESBL screening breakpoint (sensitivities of 95.2% versus 99.0%, respectively).
Comparison of DAM with CLSI and EUCAST disc contents
Sensitivities of DAM with amoxicillin/clavulanic acid (clavulanic acid serving as the ESBL inhibitor) and ceftazidime or cefotaxime discs with CLSI or EUCAST disc contents, respectively, were similar (ranging from 84.7% to 89.8%, see Table 2 ). Considering all isolates independent of the production of an AmpC-type b-lactamase, DAM with amoxicillin/clavulanic acid and cefepime displayed the highest sensitivity (96.6%). The other combinations had sensitivities less than 90%.
In AmpC-producing isolates, synergy of amoxicillin/ clavulanic-acid with cefepime showed a sensitivity and specificity of 100% and 97.9%, respectively. The other DAMs in AmpCproducing isolates showed low sensitivity (Table 3) .
Discussion
In 2010 EUCAST and CLSI changed their guidelines concerning ESBL detection and interpretation. 11, 12 Reporting of penicillins and cephalosporins as resistant, independent of in vitro results, is no longer recommended. However, detection of ESBL is still considered useful (CLSI, 2011) 13 or even mandatory (EUCAST, 2011) 14 for epidemiological purposes. Additionally, it remains controversial as to whether the presence of ESBL-producing bacterial strains alone is an independent risk factor that may influence the selection of an adequate therapy. 24 -28 CLSI inhibition zone screening breakpoints for ESBL have been evaluated in several studies, as it has for DAM. 26, 29 The current adoption of the new EUCAST guidelines in Europe raises the question of how sensitive and specific EUCAST clinical breakpoints are for third-generation cephalosporins, in comparison with CLSI values, for the detection of ESBL.
Overall, this study shows that EUCAST non-susceptible breakpoints for cefotaxime and ceftazidime with corresponding EUCAST disc contents may be used without loss of performance compared with CLSI ESBL screening breakpoints. Using the EUCAST non-susceptible breakpoints for ceftriaxone will slightly decrease sensitivity compared with the CLSI ESBL screening breakpoint. However, using the EUCAST non-susceptible breakpoint for cefpodoxime will result in a sensitivity of 100% with specificity marginally decreased compared with the CLSI ESBL screening breakpoint.
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Furthermore, EUCAST recommends lower antibiotic disc contents for ceftazidime and cefotaxime compared with CLSI. Evaluation of the influence of the new disc contents on the performance of the commonly applied DAM for ESBL detection and confirmation was another aim of this study. The sensitivities of DAM with ceftazidime and cefotaxime were found to be independent of disc contents of CLSI and EUCAST, respectively; however, these are dispensable for routine use, since other markers showed a higher sensitivity. Cefepime DAM and the EUCAST resistant breakpoint for cefpodoxime proved to be the most sensitive markers for screening of potential ESBL producers. Notably, cefepime synergy showed a sensitivity of 100% in isolates producing chromosomally encoded or plasmid-encoded AmpC b-lactamases. Our results are in agreement with other studies that found cefepime to be the most suitable substance for screening and confirmation of ESBL-producing isolates that also produce AmpC. 30, 31 Thus, for AmpC-positive isolates such as Enterobacter spp., but also for isolates with plasmid-encoded AmpC, cefepime DAM may be used as a sole screening marker for ESBL. Taking into account the high specificity (97.9%) of the cefepime DAM, positive isolates may even be reported as ESBLpositive without further confirmation.
In conclusion, changing from CLSI to EUCAST breakpoints for ESBL detection will retain or even enhance sensitivity for ESBL detection. The fear that large proportions of ESBL-producing organisms will be reported susceptible to third-and fourthgeneration cephalosporins could not be substantiated.
